➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Medtronic
Colorcon
Baxter
Harvard Business School

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

Rempex Pharms Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for REMPEX PHARMS, and when can generic versions of REMPEX PHARMS drugs launch?

REMPEX PHARMS has two approved drugs.

There are seven US patents protecting REMPEX PHARMS drugs.

There are sixty patent family members on REMPEX PHARMS drugs in twenty-four countries and thirteen supplementary protection certificates in seven countries.

Summary for Rempex Pharms
International Patents:60
US Patents:7
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Rempex Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes 10,183,034   Start Trial   Start Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes 8,680,136   Start Trial Y Y   Start Trial
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes 9,084,802   Start Trial   Start Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes 10,561,675   Start Trial   Start Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes 10,172,874   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Rempex Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2603514 122019000026 Germany   Start Trial PRODUCT NAME: VABORBACTAM, UND/ODER EIN SALZ UND/ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/18/1334 20181120
2603514 CA 2019 00015 Denmark   Start Trial PRODUCT NAME: EN KOMBINATION AF VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, OG MEROPENEM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, SAERLIGT MEROPENEM TRIHYDRAT; REG. NO/DATE: EU/1/18/1334 20181122
2603514 2019C/514 Belgium   Start Trial PRODUCT NAME: UNE COMBINAISON DE VABORBACTAM, ET / OU D'UN DE SES SELS ET / OU HYDRATES, ET DU MEROPENEME, ET / OU DE SON SEL ET / OU DE SON HYDRATE, EN PARTICULIER DU MEROPENEME TRIHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1334 20181122
2603514 300977 Netherlands   Start Trial PRODUCT NAME: EEN COMBINATIE VAN VABORBACTAM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, EN MEROPENEM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, IN HET BIJZONDER MEROPENEM TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/18/1334 20181122
2603514 19C1022 France   Start Trial PRODUCT NAME: VABORBACTAM, ET/OU UN SEL ET/OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/18/1334 20181122
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
McKesson
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.